InspireMD, Inc. (NSPR) - רווח נקי למניה (EPS TTM)

InspireMD, Inc. (NSPR) develops innovative CGuard stents for stroke prevention, expanding its presence in the US market. Production is based on the unique MicroNet technology in Germany and Israel. The TTM earnings per share demonstrate the fundamental resilience of the business, where -0.65 reflects the latest value of the metric. Efficiency is supported by the modernization of assembly lines with robotic quality control systems.

For InspireMD, Inc. (NSPR), which develops specialized cardiology stents, EPS TTM serves as a key metric for measuring the effectiveness of its niche capitalization. This metric calculates the total net income over the year divided by the total number of shares, eliminating reporting subjectivity. The current trailing twelve-month earnings per share is recorded at -0.65. This chart allows for a comparison between the business's actual returns and its expansion costs. An increase in this value confirms the sustainability of the vascular protection model.